The HMBOX1 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the HMBOX1 gene has been disrupted to create a loss-of-function model. This product provides a heterogeneous pool of edited cells derived from the SK-HEP-1 human hepatic adenocarcinoma line, enabling functional studies of HMBOX1 without clonal selection artifacts. The polyclonal format preserves population-level diversity while abrogating HMBOX1 expression, making it suitable for pooled genetic screens, bulk assays, and cancer biology investigations where averaged phenotypic readouts are desired.
SK-HEP-1 is a well-characterized hepatic adenocarcinoma cell line originally isolated from the ascitic fluid of a patient with liver cancer. Although it displays some endothelial-like features, it is widely accepted as a hepatocellular carcinoma model in both academic and pharmaceutical research. Its rapid proliferation, tumorigenic capacity in xenograft models, and genetic tractability make it a standard host for gene editing and oncology studies. The cell line retains key signaling pathways relevant to hepatocarcinogenesis, including TP53-dependent responses, thus providing a relevant background for dissecting HMBOX1-mediated processes.
HMBOX1 encodes a homeobox transcription factor that functions as a critical mediator of TP53-dependent apoptosis and cell cycle arrest following DNA damage. Mechanistically, HMBOX1 is activated downstream of ATM/ATR signaling and TP53, and it directly binds to the promoters of pro-apoptotic targets such as BAX, BBC3 (PUMA), and PMAIP1 (NOXA) to promote mitochondrial outer membrane permeabilization and caspase activation. It also transcriptionally upregulates CDKN1A (p21) to enforce G1/S checkpoint arrest. Interaction partners include TRIP13, MDM2, and the non-homologous end joining factor Ku70 (XRCC6), positioning HMBOX1 at the intersection of apoptosis, DNA repair, and cell cycle regulation.
In liver cancer cells, HMBOX1 deficiency is associated with impaired apoptotic responses and heightened genomic instability, traits that contribute to chemoresistance and tumor progression. The SK-HEP-1 background, which harbors wild-type TP53, provides a competent platform to dissect how HMBOX1 loss attenuates p53-mediated tumor suppression. Consequently, these knockout cells serve as a relevant model for studying hepatocellular carcinoma pathogenesis, including mechanisms of evasion from apoptosis and acquisition of drug resistance. They also facilitate exploration of synthetic lethal relationships with DNA damage repair defects.
Key research applications include dissection of p53 signaling, apoptosis assays (e.g., Annexin V/PI staining, caspase-3/9 activity profiling), cell cycle analysis by flow cytometry, DNA damage response studies using ??-H2AX immunofluorescence, transcriptional target validation via RT-qPCR and chromatin immunoprecipitation, and functional genomics through RNA-seq. This tool is also appropriate for drug screening campaigns targeting liver cancer vulnerabilities, combination therapy assessments, and investigation of novel HMBOX1 interactors. For further experimental protocols or technical support, please contact Ascent Research.
